Dexcom (DXCM) Cash from Operations Growth (3y) (2013 - 2026)
Dexcom (DXCM) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.66 Bn | 175.36 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.55 Bn | 125.68 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.38 Bn | 99.16 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.11 Bn | 66.66 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.19 Bn | 43.52 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.54 Bn | 27.42 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 28.37 Bn | 26.09 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.53 Bn | 22.40 Bn | 2.07 Bn | 0.50% |
| 10 | Steris | 21.52 Bn | 21.08 Bn | 697.10 Mn | 15.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.11% |
| Dec 31, 2025 | 30.43% |
| Sep 30, 2025 | 31.05% |
| Jun 30, 2025 | 20.59% |
| Mar 31, 2025 | 37.31% |
| Dec 31, 2024 | 41.76% |
| Sep 30, 2024 | -6.91% |
| Jun 30, 2024 | 65.53% |
| Mar 31, 2024 | 95.96% |
| Dec 31, 2023 | -8.08% |
| Sep 30, 2023 | 22.18% |
| Jun 30, 2023 | 7.29% |
| Mar 31, 2023 | 334.08% |
| Dec 31, 2022 | -2.67% |
| Sep 30, 2022 | 45.85% |
| Jun 30, 2022 | 38.89% |
| Mar 31, 2022 | 81.88% |
| Dec 31, 2021 | 46.43% |
| Sep 30, 2021 | 63.29% |
| Jun 30, 2021 | 14.16% |